| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Nimish P Shah is Director at APGE and has filed Form 4s across 2 companies. Nimish P Shah's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $236.5M at current prices.
The biggest single holding is APGE (~$236.4M) as Director. Net of sales, the APGE filings show accumulation of 1,750,000 shares.
Nimish P Shah has 8 Form 4 filings on record from March 2021 to September 2026, across 3 companies: Director at Korsana Biosciences (KRSA), 2026; Director at Apogee Therapeutics (APGE), 2023–2026; Director at Instil Bio (TIL), 2021.
The 18 reported transactions were 7 open-market purchases, 6 option or other derivative awards and 5 conversions.
Counted by filing, the open-market trades come to 2 purchases worth about $35.8M and no sales.
The largest open-market purchase was 1,750,000 shares of APGE at an average $17.00 on July 13, 2023, about $29.8M. Twelve months later APGE was up 126%.